Glimepirid Teva 4 mg Norge - norsk - Statens legemiddelverk

glimepirid teva 4 mg

teva sweden ab - glimepirid - tablett - 4 mg

Glimepirid Teva 1 mg Norge - norsk - Statens legemiddelverk

glimepirid teva 1 mg

teva sweden ab - glimepirid - tablett - 1 mg

Glimepirid Teva 2 mg Norge - norsk - Statens legemiddelverk

glimepirid teva 2 mg

teva sweden ab - glimepirid - tablett - 2 mg

Glimepirid Teva 3 mg Norge - norsk - Statens legemiddelverk

glimepirid teva 3 mg

teva sweden ab - glimepirid - tablett - 3 mg

Euthyrox 25 mikrog Norge - norsk - Statens legemiddelverk

euthyrox 25 mikrog

merck ab (1) - levotyroksinnatrium - tablett - 25 mikrog

Euthyrox 50 mikrog Norge - norsk - Statens legemiddelverk

euthyrox 50 mikrog

merck ab (1) - levotyroksinnatrium - tablett - 50 mikrog

Euthyrox 100 mikrog Norge - norsk - Statens legemiddelverk

euthyrox 100 mikrog

merck ab (1) - levotyroksinnatrium - tablett - 100 mikrog

Losartan/Hydrochlorothiazide Krka 100 mg / 12.5 mg Norge - norsk - Statens legemiddelverk

losartan/hydrochlorothiazide krka 100 mg / 12.5 mg

krka sverige ab - losartankalium / hydroklortiazid - tablett, filmdrasjert - 100 mg / 12.5 mg

Burinex 5 mg Norge - norsk - Statens legemiddelverk

burinex 5 mg

karo pharma ab (1) - bumetanid - tablett - 5 mg

Celsunax Den europeiske union - norsk - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne pasienter, for å kunne skille mellom sannsynlig demens med lewy legemer fra alzheimers sykdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.